drugset
drugset / Trial / NCT06842186

A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity

NCT06842186 ↗

Phase 1/2 Recruiting 296 enrolled Wave Life Sciences USA, Inc.
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in two adult populations: Pre Type 2 diabetes (Pre T2D) and Type 2 Diabetes (T2D) in adults who are affected by obesity.

Timeline

Start
2025-01-31
Primary completion
2027-12
Completion
2027-12

Drugs

EvaluationDrugModalityDoseRoute
Subject WVE-007 Small interfering RNA (siRNA) — Subcutaneous

Indications

No indication recorded.